Data offer further evidence on Akili's digital therapeutic in ADHD

26 March 2021

Akili Interactive has announced the publication of full data from a multi-site open-label study (STARS Adjunct) evaluating the impact of the digital therapeutic EndeavorRx on symptoms and functional impairments in children with attention-deficit/hyperactivity disorder (ADHD).

These results, which have been published in the journal Nature Digital Medicine, demonstrate statistically-significant improvement in all predetermined endpoints of the study including parent and clinician ratings of children’s ADHD symptoms and related impairments in daily life.

The STARS Adjunct study data, along with results from four other clinical studies of EndeavorRx in pediatric ADHD, were presented to the US Food and Drug Administration and were part of the data package that led to FDA clearance of EndeavorRx in June 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK